Recruiting
A Study to Evaluate CC-486 in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Cancer Participants - CA055-001
Mis à jour: 4 novembre, 2024 | ClinicalTrials.gov
Phase
Sexe(s)
Tranche d’âge
Site(s)
Recruiting
Inclusion Criteria: - Documented diagnosis of Myelodysplastic syndrome, Acute myeloid leukemia, Multiple myeloma, Non-Hodgkin's lymphoma, Hodgkin's lymphoma or metastatic or inoperable solid tumors - Life expectancy of ≥ 3 months - Stable renal function without dialysis for at least 2 months prior to investigational product administration - Has moderate or severe hepatic impairment as defined by National Cancer Institute Organ Dysfunction Working Group criteria Exclusion Criteria: - Chemotherapy or radiotherapy within 4 weeks prior to the first day of investigational product administration - Persistent, clinically significant non-hematologic toxicities from prior therapies which have not recovered to < Grade 2 - Any condition including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study - History of inflammatory bowel disease, celiac disease, prior gastrectomy, gastric bypass, upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with the absorption of the investigational product and/or predispose the participant to an increased risk of gastrointestinal toxicity Other protocol-defined inclusion/exclusion criteria apply
Nous vous recommandons vivement de contacter BMS pour signaler les effets secondaires (événements indésirables)
Les effets secondaires (événements indésirables) et les autres événements à signaler sont définis ici
Signaler des plaintes concernant des effets indésirables (effets indésirables) ou des produits: Informations médicales
